AngioDynamics Inc. has announced the enrollment of the first patient in the AMBITION BTK trial, a prospective, multicenter, randomized controlled trial $(RCT)$ aimed at evaluating the clinical safety and effectiveness of the Auryon Atherectomy System when used in combination with standard balloon angioplasty. This trial focuses on treating infrapopliteal lesions in patients with Critical Limb Ischemia $(CLI.UK)$, a condition with a significant risk of limb loss if untreated. The trial will involve up to 224 patients across 30 sites, with results to be presented in the future. A companion registry will also enroll up to 1,500 additional patients who are ineligible for the RCT. Further information about the study can be found on AngioDynamics' website and ClinicalTrials.gov.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.